Methodology to Incorporate the BED and EUD in PatientSpecific 3-Dimensional Dosimetry for Non-Hodgkin's Lymphoma Patients Targeted with 131I Tositumomab Therapy

被引：0
|
作者：
Amro, H.
Wilderman, S.
Dewaraja, Y.
Roberson, P.
机构：
来源：
MEDICAL PHYSICS | 2009年 / 36卷 / 06期
关键词：
D O I：
10.1118/1.3181937
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
SU-FF-T455
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tositumomab and 131I therapy in non-Hodgkin's lymphoma
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 128S - 140S
  • [2] Methodology to Incorporate Biologically Effective Dose and Equivalent Uniform Dose in Patient-Specific 3-Dimensional Dosimetry for Non-Hodgkin Lymphoma Patients Targeted with 131I-Tositumomab Therapy
    Amro, Hanan
    Wilderman, Scott J.
    Dewaraja, Yuni K.
    Roberson, Peter L.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (04) : 654 - 659
  • [3] Dosimetry of iodine I 131 tositumomab in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Zasadny, KR
    Rommelfanger, SG
    Regan, DD
    McCullough, NT
    Kroll, S
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 82P - 83P
  • [4] Therapy Response Correlation with Tumor Radio-Sensitivity for Non-Hodgkin's Lymphoma Treated with 131I Tositumomab
    Roberson, P. L.
    Wilderman, S. J.
    Avram, A. M.
    Kaminski, M. S.
    Schipper, M. J.
    Dewaraja, Y. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S336 - S336
  • [5] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [6] Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Dosik, AD
    Coleman, M
    Kostakoglu, L
    Furman, RR
    Fiore, JM
    Muss, D
    Niesvizky, R
    Shore, T
    Schuster, MW
    Stewart, P
    Vallabhajosula, S
    Goldsmith, SJ
    Leonard, JP
    CANCER, 2006, 106 (03) : 616 - 622
  • [7] Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Kaminski, MS
    Radford, JA
    Gregory, SA
    Leonard, JP
    Knox, SJ
    Kroll, S
    Wahl, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7985 - 7993
  • [8] Patient-specific characteristics correlate with the effective half-life of 131I tositumomab therapy in non-Hodgkin's lymphoma (NHL).
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Kroll, SM
    Bhatnagar, A
    Vallabhajosula, S
    Magnuson, D
    Goldsmith, SJ
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 79P - 79P
  • [9] Prediction of response to 131I Tositumomab therapy using 18F-fluorodeoxyglucose positron emission tomography in patients with non-Hodgkin's lymphoma.
    Kostakoglu, L
    Leonard, JP
    Coleman, M
    Zoe, H
    Vallabhajosula, S
    Fiore, JM
    Dreher, D
    Goldsmith, J
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 119P - 119P
  • [10] Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma
    Davies, AJ
    Rohatiner, AZS
    Howell, S
    Britton, KE
    Owens, SE
    Micallef, IN
    Deakin, DP
    Carrington, BM
    Lawrance, JA
    Vinnicombe, S
    Mather, SJ
    Clayton, J
    Foley, R
    Jan, H
    Kroll, S
    Harris, M
    Amess, J
    Norton, AJ
    Lister, TA
    Radford, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1469 - 1479
12345